Instil Bio, Inc.

Instil Bio, Inc. reported a net loss of $71.4 million for FY 2025, a slight improvement from a $74.1 million loss in FY 2024. Total operating expenses were $78.6 million, driven by in-process R&D ($10.0M), research and development ($24.7M), general and administrative ($27.2M), and restructuring and impairment charges ($16.6M). The company generated no product revenue and ended the year with $76.3 million in cash, cash equivalents, restricted cash, and marketable securities. Key developments include the discontinuation of lead candidate AXN-2510 in January 2026 and a strategic shift toward in-licensing or acquiring new therapeutic candidates. The company faces a significant debt maturity of $85.6 million in January 2027 but plans to exercise an extension option to January 2028.

Key Takeaways